ENSC Ensysce Biosciences, Inc.: Rasio total nilai perusahaan marang pendapatan

Simbol resmi perusahaan Ensysce Biosciences Inc. (ENSC)

Ensysce Biosciences operates within a secure US legal framework, which mitigates external risks. The proprietary PFAB and MPAR systems allow the company to flexibly manage pricing within the safe analgesics niche. The EV/Sales multiple currently stands at -3688.21, which helps assess the business value relative to revenue. This results in the creation of a closed patent perimeter that ties clinics to unique drug activation protocols.

Multiplikator EV/Sales Ensysce (ENSC): kanggo periode 23.11.2025 - 20.11.2026

ensysce.com - rincian analitis lan metrik utama (ENSC)

- data kapitalisasi saham perusahaan:
Pambiji fundamental perusahaan:ENSC (Ensysce)
Sampel barang Ensysce Biosciences

For Ensysce Biosciences (ENSC), which develops innovative overdose-protected analgesics, the current EV/Sales ratio reflects the enterprise value of the business net of debt relative to annual revenue. This metric measures the value of operating assets regardless of the financing structure, allowing investors to determine whether they are overpaying for the potential of technology commercialization or to identify an undervaluation of capital.